Pegylated Interferon alpha 2-b

Medical Advocates
Pegylated Interferon alfa-2b (PEG-INTRON)

HCV Conference Data

14th CROI
12th International Symposium on Viral Hepatitis and :Liver
Disease
3rd IAS Conference
XV International AIDS Conference
11th CROI

Peg Inf Alfa-2b_HBC=Primal Main Page

Main New/Newsworthy

Home Page

Last Update: January 26, 2015

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

14th Conference on Retroviruses and Opportunistic
Infections

POSTER
Predictive Factors of Severe Toxicity Associated with Pegylated Interferon and Ribavirin Treatment in
HIV/HCV-co-infected Patients
JA. Mira, B Valera-Bestard, A Arizcorreta-Yarza, et al
PDF Poster Abstract
Cut-off Values of Ribavirin Trough Concentration for Sustained Virological Response and for
Hematological Toxicity in HCV/HIV-co-infected Patients Treated with RBV and Pegylated Interferon
DA Marucco, D Gonzalez de Requena, L Veronese, et al
Abstract
POSTER
Antiretroviral Regimens including Tenofovir or Stavudine + Lamivudine as NRTI Backbone Are
Associated with Higher Sustained Virological Response Rate to Pegylated Interferon and Ribavirin
Treatment in HIV/HCV-co-infected Patients
JA Mira, R Carrillo-Gómez, A Gutierrez-Valencia, et al
PDF Poster Abstract
Factors Associated with Virological Non-response to Peg-Interferon + Ribavirin Therapy in
HIV/HCV-Co-infected Patients: The Role of Abacavir
F Bani-Sadr, L Denoeud, P Morand, et al
Abstract
POSTER
Rapid Virological Response at Week 4 Predicts Sustained Response to Pegylated
Interferon + Ribavirin among HIV/HCV-co-Infected Patients
JA Mira, B Valera-Bestard, A Arizcorreta-Yarza, et al
PDF Poster Abstract

12th International Symposium on Viral Hepatitis
and Liver Disease

Effectiveness and tolerability of pegintron(r) in combination with rebetol(r) in real life:
the pegintrust study
Adler M., Bastens . B. Colle . I., et al

Abstract

Novel sustained release formulation of ifn-a-2b improves tolerability and demonstrates potent viral load
reduction in a phase i/ii hcv clinical trial
Trepo C., Meyrueix R., Maynard M., et al
Abstract

The efficacy of a 12 weeks course of pegylated interferon alfa 2b (peg-ifn) and ribavirin (rbv) is similar to a
standard 24 weeks course, regardless of basal viremic level
Bonardi R., Manca A, Tabone M., et al
Abstract

3rd IAS Conference

Efficacy of acute HCV treatment with peg-interferon a-2b and ribavirin in HIV infected patients
Kruk A.
Abstract

XV International AIDS Conference

HCV Infection

Moderate dose of PegInterferon alfa-2b in combination with ribavirin in the treatment of HCV
patients with or without HIV
C Sarmento, A Horta, H Coelho, O Vasconcelos, et al.
Abstract

11th Conference on Retroviruses and Opportunistic
Infections

HCV Infection/Disease

Final Results of APRICOT: A Randomized, Partially Blinded, International Trial Evaluating
Peginterferon-alfa-2a + Ribavirin vs Interferon-alfa-2a + Ribavirin in the Treatment of HCV in
HIV/HCV Co-infection
FJ Torriani, J Rockstroh, M Rodriguez-Torres, et al
Abstract

HIV/HCV Infection/ Disease

Final Results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated-Interferon-
alfa-2b plus Ribavirin vs Interferon-alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C
in HIV Co-infected Patients
C Perronne, F Carrat, F Bani-Sadr, et al
Abstract

Viral Kinetics and Early Prediction of Non-response to Pegylated-IFN-alfa-2b and Ribavirin in HCV
Genotypes 1/4 according to HIV Serostatus
A Moreno, S García-Garzón, L Moreno, R Bárcena, et al
Abstract

HCV Resistance to Peg-Interferon/Ribavirin Therapy Is Associated with Increased Immune
Activation in HIV/HCV Co-infected Patients
RA Lempicki, J Yang, G Dennis, et al
Abstract

Peg Inf Alfa-2b_HBC=Primal Main Page Main New/Newsworthy Home Page

Peginterferon alfa-2b
HCV Conference Data